Cargando…

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression

BACKGROUND: The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1 inhibitors fail to derive any clinical benef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Tara L., Chen, Nan, Tyler, Logan C., Le, Anh T., Dimou, Anastasios, Doebele, Robert C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665781/ https://www.ncbi.nlm.nih.gov/pubmed/37727007 http://dx.doi.org/10.1111/1759-7714.15116

Ejemplares similares

Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation
por: Dimou, Anastasios, et al.
Publicado: (2019)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

A patient with classic biphasic pulmonary blastoma harboring CD74–ROS1 fusion responds to crizotinib
por: Meng, Zhaoting, et al.
Publicado: (2017)

SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis
por: Maiti, Guru P., et al.
Publicado: (2021)

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion
por: Xie, Xuehua, et al.
Publicado: (2022)

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma
por: Lan, Shaowei, et al.
Publicado: (2020)

A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report
por: Hu, Huiyu, et al.
Publicado: (2021)

Evolution of acquired resistance in a ROS1(+) KRAS G12C(+) NSCLC through the MAPK pathway
por: Priest, Katherine, et al.
Publicado: (2023)

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
por: Davies, Kurtis D., et al.
Publicado: (2013)

Activation of RAS family members confers resistance to ROS1 targeting drugs
por: Cargnelutti, Marilisa, et al.
Publicado: (2014)

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens
por: Tanaka, Satoshi, et al.
Publicado: (2023)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
por: Huang, Richard S.P., et al.
Publicado: (2020)

ALCAT1 Overexpression Affects Supercomplex Formation and Increases ROS in Respiring Mitochondria
por: Rieger, Bettina, et al.
Publicado: (2019)

AXL Promotes Metformin-Induced Apoptosis Through Mediation of Autophagy by Activating ROS-AMPK-ULK1 Signaling in Human Esophageal Adenocarcinoma
por: Hong, Jun, et al.
Publicado: (2022)

Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report
por: Wang, Gang, et al.
Publicado: (2020)

Overexpression of a Novel Noxo1 Mutant Increases Ros Production and Noxo1 Relocalisation
por: Benssouina, Fatima-Zahra, et al.
Publicado: (2023)

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment
por: Zhang, Xugang, et al.
Publicado: (2022)

Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
por: Sun, Wei, et al.
Publicado: (2023)

ROS and ROS-Mediated Cellular Signaling
por: Zhang, Jixiang, et al.
Publicado: (2016)

Microvesicles: ROS scavengers and ROS producers
por: Bodega, G., et al.
Publicado: (2019)

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
por: Xu, Long, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
por: Lin, Jessica J., et al.
Publicado: (2020)

NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma
por: Su, Xiangsheng, et al.
Publicado: (2021)

Nfu1 Mediated ROS Removal Caused by Cd Stress in Tegillarca granosa
por: Qian, Guang, et al.
Publicado: (2017)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

Mitochondrial ROS and the Effectors of the Intrinsic Apoptotic Pathway in Aging Cells: The Discerning Killers!
por: Hekimi, Siegfried, et al.
Publicado: (2016)

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma
por: Dimou, Anastasios, et al.
Publicado: (2020)

Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling
por: Sarkar, Oli, et al.
Publicado: (2017)

ROS and COVID
por: Vardakas, Periklis, et al.
Publicado: (2022)

Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
por: Lim, Sun Min, et al.
Publicado: (2017)

ROS mediated apoptotic pathways in primary effusion lymphoma: Comment on induction of apoptosis by Shikonin through ROS-mediated intrinsic and extrinsic pathways in primary effusion lymphoma
por: Dwivedi, Pankaj
Publicado: (2021)

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
por: Rojo, Federico, et al.
Publicado: (2022)

Redox Regulation Beyond ROS: Why ROS Should Not Be Measured as Often
por: Brandes, Ralf P., et al.
Publicado: (2018)

SATB1-dependent mitochondrial ROS production controls TCR signaling in CD4 T cells
por: Kuwabara, Taku, et al.
Publicado: (2021)

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing
por: Zhu, You‐cai, et al.
Publicado: (2018)

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
por: Sievers, Philipp, et al.
Publicado: (2021)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma
por: Grenier, Karl, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nfg936vdmc4a73i7ldfm00innq